Royalty Pharma reports third quarter 2026 results
Key Highlights
- ➤Portfolio Receipts rose 9% to $890 million in Q3 2026
- ➤Royalty Receipts increased 9% to $883 million, driven by Tremfya, Voranigo, Evrysdi and Imdelltra
- ➤2026 Portfolio Receipts guidance raised to $3,500 million-$3,550 million
- ➤Announced transactions reached $1.9 billion as of November 3, 2026
- ➤Net cash provided by operating activities totaled $686 million in Q3 2026
Expert Statements
Pablo Legorreta, Chief Executive Officer and Chairman of the Board of Royalty Pharma
“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance. We delivered 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date. We continued to strengthen our portfolio by adding royalties on three innovative therapies in the third quarter. We have also seen tremendous clinical and regulatory progress across our portfolio, including FDA approvals of Revolution Medicines’ Rasonque and Teva’s Weltruza and positive Phase 3 results for Amgen’s Imdelltra. Lastly, we remain excited by the potential for R&D co-funding with global biopharma - where we have announced $1 billion of transactions so far this year - which represents an important new opportunity for our business. Looking ahead, with a robust deal pipeline and strong fundamental tailwinds supporting our business, we remain well positioned as a premier capital allocator in life sciences to deliver consistent, compounding growth.”
* Portfolio Receipts growth of 9% to $890 million; Royalty Receipts growth of 9% * Net cash provided by operating activities of $686 million * Raised full year 2026 guidance: Portfolio Receipts expected to be $3,500 million to $3,550 million NEW YORK, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2026 and raised full year 2026 guidance for Portfolio Receipts.
“Royalty Pharma delivered excellent third quarter 2026 results and we again raised our financial guidance,” said Pablo Legorreta, Royalty Pharma’s Chief Executive Officer and Chairman of the Board. “We delivered 9% growth in Royalty Receipts for the quarter and double-digit growth year-to-date. We continued to strengthen our portfolio by adding royalties on three innovative therapies in the third quarter. We have also seen tremendous clinical and regulatory progress across our portfolio, including FDA approvals of Revolution Medicines’ Rasonque and Teva’s Weltruza and positive Phase 3 results for Amgen’s Imdelltra. Lastly, we remain excited by the potential for R&D co-funding with global biopharma - where we have announced $1 billion of transactions so far this year - which represents an important new opportunity for our business. Looking ahead, with a robust deal pipeline and strong fundamental tailwinds supporting our business, we remain well positioned as a premier capital allocator in life sciences to deliver consistent, compounding growth.”
Get started
Create a free account to read the full story.